Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Blood|December 20, 2013
Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cellsSamuel G Katz, James L Labelle, Hailong Meng, et al.
Psycho-Oncology|August 20, 2025
A Hybrid Effectiveness-Implementation Study of the Managing Cancer and Living Meaningfully Psychosocial Intervention Across Established Psychosocial Oncology and Palliative Care Programs in Alberta's Calgary and South ZoneJ M de Groot, A Feldstain, C Sears, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2023
Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expressionSean P Rinella, Haley C Bell, Nicholas J Hess, et al.
Annals of Translational Medicine|June 24, 2024
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patientsGong He, Erika Belmont, Theodore Karrison, et al.
The Journal of Clinical Investigation|May 25, 2012
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancersJames L LaBelle, Samuel G Katz, Gregory H Bird, et al.
Signal Transduction and Targeted Therapy|April 26, 2026
Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changesNada S Aboelella, Ryan Park, Erting Tang, et al.
Experimental Hematology & Oncology|January 10, 2019
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplantYun Fan, Andrew S Artz, Koen van Besien, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2022
Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell functionKatrina M Hawley, Rachel J Eclov, Mathew R Schnorenberg, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment EfficacyErting Tang, Yifei Hu, Guoshuai Cao, et al.
Blood Advances|July 19, 2022
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCTMisha C Tran, Yasmin Hasan, Amy Wang, et al.
Pageof 9